Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III non-inferiority trial of a 13-valent pneumococcal conjugate vaccine in infants and children
CTR20213373Phase 3Active
- Sponsor
- AIM Vaccine Co., Ltd.
- Start
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of 13-valent pneumococcal polysaccharide conjugate vaccine in invasive pneumococcal disease (IPD), sponsored by AIM Vaccine Co., Ltd.. Started Feb 2022; status: active.
02
Drugs
13-valent pneumococcal polysaccharide conjugate vaccine
03
Conditions
invasive pneumococcal disease (IPD)
Beyond the preview
Go deeper on CTR20213373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213373.